Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

A prior industry-funded, randomized, phase III trial of 713 patients with local-regionally advanced non–small-cell lung cancer (NSCLC; PACIFIC; NEJM JW Oncol Hematol Nov 2017 and N Engl J Med 2017; 377:1919) showed that at a median follow-up of 14.5 months, those who received consolidation therapy with the PD-L1 inhibitor durvalumab versus placebo for 1 year had superior median progression-free survival (PFS; 16.8 vs. 5.6 months; P<0.0001), a higher response rate (28.4% vs. 16%; P<0.001), and a longer median time to distant metastases or death (23.2 vs. 14.6 months; P<0.001).

Now, the PACIFIC investigators report that at a median follow-up of 25.2 months, patients who received durvalumab versus placebo consolidation therapy had superior 2-ye…